Your browser is no longer supported. Please, upgrade your browser.
Settings
VVUS VIVUS, Inc. daily Stock Chart
VVUS [NASD]
VIVUS, Inc.
Index- P/E- EPS (ttm)-3.48 Insider Own2.50% Shs Outstand10.77M Perf Week6.45%
Market Cap38.99M Forward P/E- EPS next Y-4.77 Insider Trans12.30% Shs Float9.73M Perf Month-13.40%
Income-37.00M PEG- EPS next Q-1.17 Inst Own18.00% Short Float6.64% Perf Quarter-10.62%
Sales65.10M P/S0.60 EPS this Y-21.90% Inst Trans-0.67% Short Ratio7.98 Perf Half Y-11.71%
Book/sh-3.76 P/B- EPS next Y-1.30% ROA-12.70% Target Price10.00 Perf Year-4.74%
Cash/sh10.32 P/C0.35 EPS next 5Y0.80% ROE119.40% 52W Range2.15 - 9.88 Perf YTD62.33%
Dividend- P/FCF- EPS past 5Y27.40% ROI-0.80% 52W High-64.17% Beta2.16
Dividend %- Quick Ratio3.30 Sales past 5Y-4.30% Gross Margin77.40% 52W Low64.65% ATR0.21
Employees57 Current Ratio3.90 Sales Q/Q68.90% Oper. Margin-5.30% RSI (14)37.70 Volatility7.72% 5.87%
OptionableYes Debt/Eq- EPS Q/Q54.00% Profit Margin-56.80% Rel Volume0.75 Prev Close3.62
ShortableYes LT Debt/Eq- EarningsApr 30 AMC Payout- Avg Volume80.87K Price3.54
Recom- SMA20-4.93% SMA50-19.03% SMA200-22.76% Volume12,358 Change-2.21%
May-04-16Downgrade WallachBeth Buy → Hold
Nov-05-15Upgrade WallachBeth Hold → Buy $2.30 → $2.80
Jul-31-15Reiterated RBC Capital Mkts Outperform $6 → $4
Jan-23-15Initiated RBC Capital Mkts Outperform $6
Feb-25-14Reiterated WallachBeth Hold $11 → $8
Nov-15-13Initiated WallachBeth Hold $11
Oct-03-13Upgrade Cowen Hold → Outperform $19
Jul-19-13Downgrade Needham Buy → Hold
Jan-18-13Reiterated MLV & Co Buy $40 → $21
Sep-24-12Reiterated Needham Buy $38 → $32
Jul-19-12Reiterated MLV & Co Buy $34 → $40
Jul-18-12Reiterated Rodman & Renshaw Mkt Outperform $39 → $52
Jul-18-12Downgrade Brean Murray Buy → Hold
Apr-30-12Reiterated MLV & Co Buy $30 → $34
Feb-23-12Upgrade Rodman & Renshaw Mkt Perform → Mkt Outperform $39
Feb-23-12Upgrade Brean Murray Sell → Hold $2
Feb-23-12Reiterated MLV & Co Buy $22 → $30
Feb-23-12Reiterated JMP Securities Mkt Outperform $16 → $45
Jan-17-12Reiterated MLV & Co Buy $16 → $22
Jan-05-12Initiated Rodman & Renshaw Mkt Perform
Apr-16-19 07:30AM  VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, April 30, 2019 GlobeNewswire
Mar-14-19 07:30AM  VIVUS Announces Marketing Approval of Avanafil in the Russian Federation for the Treatment of Erectile Dysfunction ACCESSWIRE
Feb-28-19 08:47PM  Edited Transcript of VVUS earnings conference call or presentation 26-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
Feb-26-19 04:05PM  VIVUS Reports Fourth Quarter 2018 Financial Results GlobeNewswire
Feb-13-19 07:30AM  VIVUS to Host Fourth Quarter and Full Year Business Update and Financial Results Conference Call on Tuesday, February 26, 2019 GlobeNewswire
Feb-05-19 03:02PM  3 Biotech Stocks That Pay Solid Dividends InvestorPlace +6.09%
Feb-04-19 04:00PM  VIVUS Announces Date of 2019 Annual Meeting GlobeNewswire
Jan-15-19 07:55AM  Today's Research Reports on Trending Tickers: Array BioPharma and VIVUS ACCESSWIRE
Jan-14-19 07:30AM  Data Supporting the Cardiovascular Safety of VIVUS Qsymia® Published in The Journal of Clinical Endocrinology & Metabolism GlobeNewswire +38.20%
Jan-03-19 03:29PM  VIVUS (VVUS) Banks on New Drug Pancreaze, Qsymia Lacks Luster Zacks
Dec-27-18 07:30AM  VIVUS to Present at Biotech Showcase on January 9, 2019 GlobeNewswire
Dec-25-18 12:28PM  Do Institutions Own Shares In VIVUS, Inc. (NASDAQ:VVUS)? Simply Wall St.
Dec-14-18 07:59AM  5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride Zacks
Dec-13-18 07:56AM  The Daily Biotech Pulse: Vivus Extends Supply Deal With Sandoz, Applied Genetic Snaps Ties With Biogen Benzinga
Dec-01-18 09:31AM  Vivus (VVUS) Down 17% Since Last Earnings Report: Can It Rebound? Zacks
Nov-15-18 08:25AM  New Research Coverage Highlights CommVault, Dawson Geophysical, RF Industries, Hennessy Advisors, VIVUS, and Semiconductor Manufacturing International Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-07-18 07:16AM  Edited Transcript of VVUS earnings conference call or presentation 1-Nov-18 8:30pm GMT Thomson Reuters StreetEvents
Nov-02-18 11:31AM  VIVUS (VVUS) Q3 Loss Narrower Than Expected, Revenues Up Y/Y Zacks +19.65%
Nov-01-18 07:36PM  Vivus: 3Q Earnings Snapshot Associated Press
04:10PM  VIVUS Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-29-18 07:30AM  VIVUS Adds Two New Members to the Board of Directors GlobeNewswire
Oct-26-18 07:30AM  VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Thursday, November 1, 2018 GlobeNewswire
Oct-10-18 07:30AM  VIVUS to Present at the BIO Investor Forum on October 17, 2018 GlobeNewswire
Sep-26-18 07:30AM  VIVUS Regains Compliance with Nasdaq Listing Requirements GlobeNewswire
Sep-24-18 07:30AM  VIVUS to Present at the Fourth Annual Robins Equity Research Round-Up GlobeNewswire
Sep-21-18 07:30AM  VIVUS Supports the Cystic Fibrosis Community Through Sponsorship of and Participation in the Cystic Fibrosis Foundations CF Climb GlobeNewswire
Sep-11-18 10:57AM  Vivus stock rallies above $5 mark in volatile trade after reverse stock split takes effect MarketWatch +9.34%
10:35AM  New Growth Opportunities Jump for 3 Biotech Stocks in 2018 ACCESSWIRE
Sep-10-18 07:30AM  VIVUS Announces 1-for-10 Reverse Stock Split GlobeNewswire -15.89%
Sep-06-18 11:31AM  Why Is Vivus (VVUS) Down 6.4% Since Last Earnings Report? Zacks -5.48%
Aug-27-18 07:30AM  VIVUS Reports Data Supporting the Cardiovascular Safety of Qsymia® GlobeNewswire
Aug-22-18 09:07AM  VIVUS' (VVUS) Qsymia Falters in a Highly Competitive Market Zacks
07:30AM  VIVUS to Present at the H.C. Wainwright 20th Annual Global Investment Conference on September 5, 2018 GlobeNewswire
Aug-21-18 09:40AM  Edited Transcript of VVUS earnings conference call or presentation 7-Aug-18 8:30pm GMT Thomson Reuters StreetEvents
Aug-08-18 10:14AM  VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y Zacks
Aug-07-18 07:03PM  Vivus: 2Q Earnings Snapshot Associated Press
04:05PM  VIVUS Reports Second Quarter 2018 Financial Results GlobeNewswire
02:30PM  VIVUS, Inc. to Host Earnings Call ACCESSWIRE
Aug-06-18 07:30AM  VIVUS Appoints Kenneth Suh as President GlobeNewswire
Jul-31-18 07:30AM  VIVUS to Host Second Quarter Business Update and Financial Results Conference Call on Tuesday, August 7, 2018 GlobeNewswire -5.73%
Jul-11-18 09:14AM  VIVUS' PAH Candidate Data Positive in Early Stage Study Zacks -5.14%
08:31AM  VIVUS, Inc. (VVUS) Soars: Stock Adds 10.1% in Session Zacks
Jul-10-18 07:30AM  VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106 GlobeNewswire +10.14%
Jun-15-18 07:30AM  3 Biotech Stocks Up in the Past Month on Industry Turnaround InvestorPlace
Jun-11-18 09:32AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:51AM  Can The Uptrend Continue for VIVUS (VVUS)? Zacks
07:30AM  VIVUS Executes on its Strategic Vision with the Closing of its Acquisition of PANCREAZE® and Previously Announced Financing Transaction GlobeNewswire
Jun-05-18 10:10AM  3 Biotech Stocks Up in the Past Month on Industry Turnaround Zacks
May-30-18 07:25AM  Complimentary Technical Snapshots on VIVUS and Three More Biotech Stocks ACCESSWIRE
May-25-18 08:44AM  VIVUS (VVUS) in Focus: Stock Moves 5.6% Higher Zacks
May-22-18 07:53AM  Biotech CEO Presents: Mercks $500M Pain, Our Potential Gain ACCESSWIRE +6.81%
May-17-18 08:00AM  Todays Research Reports on Stocks to Watch: Eleven Biotherapeutics and VIVUS ACCESSWIRE -5.41%
May-13-18 09:41PM  Edited Transcript of VVUS earnings conference call or presentation 8-May-18 8:30pm GMT Thomson Reuters StreetEvents
May-10-18 10:29AM  VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters Zacks
May-08-18 07:09PM  Vivus: 1Q Earnings Snapshot Associated Press -7.11%
04:05PM  VIVUS Reports First Quarter 2018 Financial Results GlobeNewswire
May-04-18 04:05PM  VIVUS Announces Date of 2018 Annual Meeting GlobeNewswire
May-03-18 08:05AM  VIVUS, Inc., New Team, New Acquisition Agreement, New Product, Analysts Review ACCESSWIRE +10.87%
07:30AM  Blog Exposure - VIVUS to Acquire Janssen Pharmas PANCREAZE(R) Capsules in the United States and Canada ACCESSWIRE
May-02-18 08:10AM  Todays Research Reports on Stocks to Watch: Avinger and VIVUS ACCESSWIRE -14.74%
May-01-18 07:05AM  VIVUS Expands its Commercial Product Portfolio with the Acquisition of PANCREAZE® GlobeNewswire +46.68%
07:00AM  VIVUS Restructures Debt and Gains Access to New Capital GlobeNewswire
Apr-30-18 04:20PM  VIVUS Strengthens Executive Leadership Team Marketwired
Apr-25-18 04:05PM  VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, May 8, 2018 Marketwired
Apr-12-18 09:50AM  Why Is VIVUS (VVUS) Down 18% Since its Last Earnings Report? Zacks
Mar-13-18 04:15PM  Vivus reports 4Q loss Associated Press -9.46%
04:05PM  VIVUS Reports Fourth Quarter 2017 Financial Results Marketwired
Feb-09-18 08:30AM  Todays Research Reports on Trending Tickers: Arena Pharmaceuticals and VIVUS ACCESSWIRE -10.73%
Dec-26-17 04:05PM  VIVUS Announces Change in Leadership Marketwired
Dec-22-17 11:51AM  ETFs with exposure to VIVUS, Inc. : December 22, 2017 Capital Cube
Dec-11-17 02:15PM  ETFs with exposure to VIVUS, Inc. : December 11, 2017 Capital Cube
Dec-01-17 10:49AM  ETFs with exposure to VIVUS, Inc. : December 1, 2017 Capital Cube
Nov-20-17 01:34PM  ETFs with exposure to VIVUS, Inc. : November 20, 2017 Capital Cube
Nov-13-17 06:55PM  Edited Transcript of VVUS earnings conference call or presentation 7-Nov-17 9:30pm GMT Thomson Reuters StreetEvents
Nov-10-17 12:55PM  ETFs with exposure to VIVUS, Inc. : November 10, 2017 Capital Cube
Nov-09-17 09:09AM  VIVUS (VVUS) Q3 Loss Narrows, Qsymia Falters, Shares Down Zacks
08:45AM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 Capital Cube
Nov-07-17 04:57PM  Vivus reports 3Q loss Associated Press
04:05PM  VIVUS Reports Third Quarter 2017 Financial Results Marketwired
10:40AM  VIVUS, Inc. to Host Earnings Call ACCESSWIRE
Nov-02-17 07:00AM  VIVUS Completes Tacrolimus Pre-IND Meeting With FDA Marketwired
Oct-31-17 08:00AM  VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017 Marketwired +5.59%
Oct-30-17 12:22PM  ETFs with exposure to VIVUS, Inc. : October 30, 2017 Capital Cube -6.75%
Oct-20-17 10:28AM  ETFs with exposure to VIVUS, Inc. : October 20, 2017 Capital Cube
Oct-09-17 12:11PM  ETFs with exposure to VIVUS, Inc. : October 9, 2017 Capital Cube
Oct-06-17 09:17AM  VIVUS, Inc. :VVUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017 Capital Cube
Sep-28-17 09:25AM  Orexigen's (OREX) Contrave Sales Improving on Promotions Zacks
Sep-08-17 08:00AM  VIVUS, Aggressive Marketing For Approved Drugs, Milestone for Tacrolimus, Pipeline Analysis ACCESSWIRE
Sep-06-17 06:09PM  VIVUS Gives Rights to Alvogen in Korea for Anti-Obesity Drug Zacks
04:05PM  VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension Marketwired
Sep-05-17 08:00AM  VIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea Marketwired
Sep-04-17 08:29AM  VIVUS (VVUS) Down 19.8% Since Earnings Report: Can It Rebound? Zacks
Aug-30-17 04:05PM  VIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation Marketwired
Aug-22-17 08:00AM  VIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017 Marketwired
Aug-10-17 08:00AM  Vivus Pipeline Review, Analysis and Potential Catalysts ACCESSWIRE
Aug-07-17 09:40AM  VIVUS (VVUS) Q2 Loss In Line with Estimates, Sales Down Y/Y Zacks
Aug-03-17 04:15PM  VIVUS Reports Second Quarter 2017 Financial Results Marketwired
Jul-06-17 10:06AM  VIVUS Settles with Teva on Weight Management Drug Generic Zacks
Jul-05-17 04:15PM  VIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation Marketwired
Jul-03-17 10:11AM  BioMarin Files BLA for Phenylketonuria Candidate Pegvaliase Zacks
VIVUS, Inc. operates as a specialty pharmaceutical company primarily in the United States and the European Union. The company offers Qsymia for the treatment of obesity as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body-mass index of 30 or greater (obese patients) or 27 or greater (overweight patients) in the presence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, or high cholesterol. It also provides PANCREAZE to treat exocrine pancreatic insufficiency due to cystic fibrosis or other conditions; and STENDRA/SPEDRA, an oral phosphodiesterase type 5 inhibitor for erectile dysfunction. In addition, the company is developing Qsymia, which has completed Phase II clinical study for treating various diseases, including obstructive sleep apnea, diabetes, and nonalcoholic steatohepatitis; and VI-0106 that has completed Phase IIa study to treat patients with pulmonary arterial hypertension. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation; Menarini Group; Sanofi; Metuchen Pharmaceuticals, LLC; Selten Pharma, Inc.; Alvogen Malta Operations (ROW) Ltd; and Janssen Pharmaceuticals, Inc. VIVUS, Inc. was founded in 1991 and is headquartered in Campbell, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Amos John P.Chief Executive OfficerMar 01Buy4.8511,00053,3841,719,500Mar 04 04:43 PM
Roberts Eric WDirectorFeb 28Buy4.828,50040,98216,660Mar 04 04:45 PM
Oki Mark KChief Financial Officer & CAONov 06Buy4.0710,00040,70010,000Nov 07 04:10 PM
ROSENMAN HERMDirectorJun 29Option Exercise0.7025,00017,500311,671Jul 03 04:10 PM
ROSENMAN HERMDirectorJun 01Buy0.7750,00038,50050,000Jun 05 09:31 PM
ROSENMAN HERMDirectorMay 29Buy0.7950,00039,500286,671May 31 04:33 PM
ROSENMAN HERMDirectorMay 21Option Exercise0.7075,00052,500136,671May 23 05:05 PM
ROSENMAN HERMDirectorMay 21Buy0.81100,00081,000236,671May 23 05:05 PM
Amos John P.Chief Executive OfficerMay 18Buy0.77270,000208,0891,710,000May 22 05:08 PM
Amos John P.Chief Executive OfficerMay 18Sale0.771,5001,1561,708,500May 22 05:08 PM
Amos John P.Chief Executive OfficerMay 17Buy0.69360,000249,2281,440,000May 21 07:16 PM
Amos John P.Chief Executive OfficerMay 16Buy0.58270,000156,5461,080,000May 17 05:00 PM
Amos John P.Chief Executive OfficerMay 15Buy0.54270,000146,529810,000May 17 05:00 PM
Amos John P.Chief Executive OfficerMay 14Buy0.51270,000138,672540,000May 15 07:39 PM
Amos John P.Chief Executive OfficerMay 11Buy0.52270,000139,914270,000May 15 07:39 PM